These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7319 related articles for article (PubMed ID: 23316667)

  • 1. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for malignant melanoma.
    Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
    Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
    Robert C; Mateus C
    Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
    Lens M; Testori A; Ferucci PF
    Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab for advanced melanoma: a nursing perspective.
    Ledezma B
    Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
    Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 366.